| Size | Price | |
|---|---|---|
| Other Sizes |
| ADME/Pharmacokinetics |
Absorption, Distribution and Excretion
Biliary excretion kinetics analysis of intravenously injected [(3)H]methyl orange and its demethylated products (monomethyl and dimethyl) showed that successive removal of methyl groups significantly accelerated the bile excretion rate of CMPD. A one-compartment pharmacokinetic model was illustrated using the bile excretion of methyl orange and its metabolites 4'-sulfo-4-methylaminoazobenzene and 4'-sulfo-4-aminoazobenzene via intravenous injection in rats as an example, in which the drug underwent two consecutive metabolic processes. Metabolism/Metabolites 4'-methylaminoazobenzene-4-sulfonic acid was generated in rats and mice. /From Table/ Methyl orange was converted to N,N-dimethyl-p-phenylenediamine by intestinal anaerobic bacteria. Sulfanilic acid is another metabolite. |
|---|---|
| References | |
| Additional Infomation |
Sodium 4-dimethylaminoazobenzene-4-sulfonate is an orange powder. (NTP, 1992)
|
| Molecular Formula |
C14H14N3NAO3S
|
|---|---|
| Molecular Weight |
327.33
|
| Exact Mass |
327.065
|
| CAS # |
547-58-0
|
| Related CAS # |
502-02-3 (Parent)
|
| PubChem CID |
23673835
|
| Appearance |
Orange to red solid powder
|
| Density |
0.987 g/mL at 25 °C
|
| Boiling Point |
100ºC
|
| Melting Point |
300 °C
|
| Flash Point |
37 °C
|
| LogP |
4.152
|
| Hydrogen Bond Donor Count |
0
|
| Hydrogen Bond Acceptor Count |
6
|
| Rotatable Bond Count |
4
|
| Heavy Atom Count |
22
|
| Complexity |
448
|
| Defined Atom Stereocenter Count |
0
|
| SMILES |
S(C1C([H])=C([H])C(=C([H])C=1[H])/N=N/C1C([H])=C([H])C(=C([H])C=1[H])N(C([H])([H])[H])C([H])([H])[H])(=O)(=O)[O-].[Na+]
|
| InChi Key |
STZCRXQWRGQSJD-UHFFFAOYSA-M
|
| InChi Code |
InChI=1S/C14H15N3O3S.Na/c1-17(2)13-7-3-11(4-8-13)15-16-12-5-9-14(10-6-12)21(18,19)20;/h3-10H,1-2H3,(H,18,19,20);/q;+1/p-1
|
| Chemical Name |
sodium;4-[[4-(dimethylamino)phenyl]diazenyl]benzenesulfonate
|
| Synonyms |
Methyl Orange NSC9416 NSC-9416NSC 9416
|
| HS Tariff Code |
2934.99.9001
|
| Storage |
Powder -20°C 3 years 4°C 2 years In solvent -80°C 6 months -20°C 1 month |
| Shipping Condition |
Room temperature (This product is stable at ambient temperature for a few days during ordinary shipping and time spent in Customs)
|
| Solubility (In Vitro) |
DMSO : ~62.5 mg/mL (~190.94 mM)
|
|---|---|
| Solubility (In Vivo) |
Solubility in Formulation 1: ≥ 2.08 mg/mL (6.35 mM) (saturation unknown) in 10% DMSO + 40% PEG300 + 5% Tween80 + 45% Saline (add these co-solvents sequentially from left to right, and one by one), clear solution.
For example, if 1 mL of working solution is to be prepared, you can add 100 μL of 20.8 mg/mL clear DMSO stock solution to 400 μL PEG300 and mix evenly; then add 50 μL Tween-80 to the above solution and mix evenly; then add 450 μL normal saline to adjust the volume to 1 mL. Preparation of saline: Dissolve 0.9 g of sodium chloride in 100 mL ddH₂ O to obtain a clear solution. Solubility in Formulation 2: ≥ 2.08 mg/mL (6.35 mM) (saturation unknown) in 10% DMSO + 90% (20% SBE-β-CD in Saline) (add these co-solvents sequentially from left to right, and one by one), clear solution. For example, if 1 mL of working solution is to be prepared, you can add 100 μL of 20.8 mg/mL clear DMSO stock solution to 900 μL of 20% SBE-β-CD physiological saline solution and mix evenly. Preparation of 20% SBE-β-CD in Saline (4°C，1 week): Dissolve 2 g SBE-β-CD in 10 mL saline to obtain a clear solution. (Please use freshly prepared in vivo formulations for optimal results.) |
| Preparing Stock Solutions | 1 mg | 5 mg | 10 mg | |
| 1 mM | 3.0550 mL | 15.2751 mL | 30.5502 mL | |
| 5 mM | 0.6110 mL | 3.0550 mL | 6.1100 mL | |
| 10 mM | 0.3055 mL | 1.5275 mL | 3.0550 mL |
*Note: Please select an appropriate solvent for the preparation of stock solution based on your experiment needs. For most products, DMSO can be used for preparing stock solutions (e.g. 5 mM, 10 mM, or 20 mM concentration); some products with high aqueous solubility may be dissolved in water directly. Solubility information is available at the above Solubility Data section. Once the stock solution is prepared, aliquot it to routine usage volumes and store at -20°C or -80°C. Avoid repeated freeze and thaw cycles.
Calculation results
Working concentration： mg/mL；
Method for preparing DMSO stock solution： mg drug pre-dissolved in μL DMSO (stock solution concentration mg/mL). Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug.
Method for preparing in vivo formulation:：Take μL DMSO stock solution, next add μL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH2O，mix and clarify.
(1) Please be sure that the solution is clear before the addition of next solvent. Dissolution methods like vortex, ultrasound or warming and heat may be used to aid dissolving.
(2) Be sure to add the solvent(s) in order.
| NCT Number | Recruitment | interventions | Conditions | Sponsor/Collaborators | Start Date | Phases |
| NCT00811889 | COMPLETED | Other: Placebo Drug: Bardoxolone Methyl (RTA 402) |
Chronic Kidney Disease Diabetic Nephropathy Type 2 Diabetes |
Reata, a wholly owned subsidiary of Biogen | 2009-04-30 | Phase 2 |
| NCT04483466 | ENROLLING BY INVITATION | Drug: Methotrexate Drug: Placebo |
Investigate the Effect(s) of Methotrexate Treatment on Arthritis Disease Severity | George Washington University | 2023-07-18 | Phase 3 |
| NCT04372615 | RECRUITING | Drug: Inebilizumab Drug: Placebo |
Autoimmune Encephalitis Encephalitis |
University of Utah | 2022-03-30 | Phase 2 |
| NCT01824875 | ACTIVE, NOT RECRUITINGWITH RESULTS | Drug: temozolomide Drug: capecitabine |
Gastrinoma Glucagonoma Insulinoma Islet Cell Carcinoma |
ECOG-ACRIN Cancer Research Group | 2013-08-08 | Phase 2 |
| NCT04044664 | COMPLETEDWITH RESULTS | Drug: Placebo oral capsule Drug: NYX-783 |
Post-Traumatic Stress Disorder | Aptinyx | 2019-01-25 | Phase 2 |
Products are for research use only; We do not sell to patients
Copyright 2020 InvivoChem LLC | All Rights Reserved
